Literature DB >> 19169028

Today's approach to the critically ill patient with acute kidney injury.

Zaccaria Ricci1, Claudio Ronco.   

Abstract

The present review describes recent evidence on all aspects relating to acute kidney injury (AKI): epidemiology, definition, diagnosis, medical and extracorporeal therapy. AKI is often underrecognized, but its outcome still remains unfavorable. In this light, definition, classification and diagnosis of AKI are fundamental today and may be reliably based on recently proposed RIFLE (risk, injury, failure, loss of function, end-stage kidney disease) classification. Pharmacological therapy of AKI is still scarcely effective, but renal replacement therapy has progressed to a more accurate and safe treatment and new interesting high-level trials and observational studies have been performed and are reviewed and commented. In the near future, however, only increased awareness of AKI incidence and early treatment or prevention of kidney injury progression will hopefully improve outcome of critically ill patients with renal failure.

Entities:  

Mesh:

Year:  2009        PMID: 19169028     DOI: 10.1159/000167019

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  3 in total

1.  Serum interleukin-18 at commencement of renal replacement therapy predicts short-term prognosis in critically ill patients with acute kidney injury.

Authors:  Chan-Yu Lin; Chih-Hsiang Chang; Pei-Chun Fan; Ya-Chung Tian; Ming-Yang Chang; Chang-Chyi Jenq; Cheng-Chieh Hung; Ji-Tseng Fang; Chih-Wei Yang; Yung-Chang Chen
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 2.  The role of medications and their management in acute kidney injury.

Authors:  Bradford L McDaniel; Michael L Bentley
Journal:  Integr Pharm Res Pract       Date:  2015-05-18

Review 3.  Pathomechanisms in the Kidneys in Selected Protozoan Parasitic Infections.

Authors:  Karolina Kot; Natalia Łanocha-Arendarczyk; Michał Ptak; Aleksandra Łanocha; Elżbieta Kalisińska; Danuta Kosik-Bogacka
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.